VeraDermics (MANE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$23.5M

Net income growth (year over year)

−50.22%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

−$69.60

Book value per share

$19.47

P/E (trailing twelve months)

—

Price to book

6.29

Debt to assets

1.47%

Payout ratio

—

Dividend yield

—

Company profile

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

• How do I buy stock in VeraDermics (MANE)?

  MANE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.